Evidence shows that Bcl-2 family members play a direct role in the development of some human malignancies. However, the mechanism by which Bcl-2 may influence tumor cell invasion and metastasis remains unclear. Ectopic overexpression of Bcl-2 in the human squamous carcinoma cell line HSC-3 enhanced tumorigenicity and experimental pulmonary metastasis. Interestingly, Bcl-2-expressing cells showed morphologic changes that resembled that of cells with an epithelial-mesenchymal transition phenotype. Analysis revealed increased N-cadherin and vimentin expression in parallel with attenuated E-cadherin level, along with enhanced migration and invasive behavior. Zymography studies confirmed elevated levels of matrix metalloproteinase-9 (MMP-9) in media of Bcl-2-expressing cells. siRNA-mediated suppression of N-cadherin expression not only prevented the enhanced invasion but also blocked the increased MMP-9 expression induced by elevated Bcl-2 expression. Accordingly, pharmacologic inhibition of MMP-9 abrogated the increased tumor cell invasion. Furthermore, the Bcl-2-mediated increase in MMP-9 expression and tumor cell invasion was dependent on fibroblast growth factor receptor-1 or extracellular signal-regulated kinase signaling. Collectively, the data establish that Bcl-2 overexpression in squamous carcinoma cells induces a partial epithelial to mesenchymal transition that promotes not only survival but also invasion and metastasis through the N-cadherin/fibroblast growth factor receptor/extracellular signal-regulated kinase pathway. Mol Cancer Res; 8(2); 170-82. ©2010 AACR.
Introduction
Despite the significant advancements in surgery, radiation, and chemotherapy, only about half of individuals diagnosed with head and neck squamous cell carcinoma (HNSCC) will survive for 5 years (1) . HNSCC spreads by local and distant metastasis, and it is this aspect of the disease that is the most challenging for developing successful clinical approaches to therapy. The rich lymphatic drainage from the oral cavity and the highly invasive behavior of HNSCC facilitate the early spread to regional lymph nodes. A priority is to gain a better understanding of the underlying mechanisms regulating the invasive and metastatic behavior of this malignancy.
The metastatic cascade consists of a series of sequential steps that include initial invasion of surrounding tissue, intravasation, and downstream vascular transport of embolic tumor cells; arrest and extravasation; and establishment of metastatic foci at new sites. However, this process is highly selective and few embolic tumor cells are successful in generating metastatic lesions at secondary sites. It is generally accepted that metastatic efficiency is related to the ability of tumor cells to resist programmed cell death and that apoptotic pathways may be dysregulated in metastatic tumor cells (2) . The coordinated signaling generated through extracellular matrix (ECM) adhesion and growth factors are essential for normal epithelial cell survival, growth, and proliferation (3, 4) . Various events, such as loss of intercellular or cell-ECM adhesion, amorphosis, and loss of the actin cytoskeleton can trigger apoptosis. Depriving normally adherent tumor cells of ECM anchorage can lead to cellular stress that eventually may initiate programmed cell death or anoikis (5, 6) .
Multiple pathways can lead to apoptosis, including the death receptor pathway and the mitochondrial-mediated pathway (7, 8) . Members of the Bcl-2 family can modulate the apoptotic pathway. The Bcl-2 family includes antiapoptotic members, such as Bcl-2, Bcl-xl, and Mcl-1. Bcl-2 is one of the key regulators of apoptosis because it confers a survival advantage on cells by protecting cells from apoptotic death (9) and is crucial in a wide variety of biological processes including embryogenesis and tissue homeostasis. Additional evidence suggests a role for Bcl-2 family members in other functions such as chemoresistance (10, 11) , cell cycle regulation (12) , angiogenesis (13, 14) , and regulation of gene expression (15) . Dysregulation of Bcl-2 expression, which results in abnormal cell growth, certainly contributes to the development of some tumors (10) . Abnormally high levels of Bcl-2 are predicted to occur in more than half of all human cancers (16) . Elevated expression of Bcl-2 in some tumors is often associated with shorter survival time and generally poorer clinical outcomes (17, 18) . Furthermore, overexpression of Bcl-2 is associated with enhanced invasion and metastasis (19) (20) (21) (22) (23) . Previous work shows that overexpression of Bcl-2 affects the expression of E-cadherin and can variably promote epithelial cells to epithelial-mesenchymal conversions (24) . It has also been suggested that RelB-induced invasive properties in breast cancer cells are mediated through Bcl-2 (25) . However, it remains unclear if this is a direct consequence of increased cell survival or if Bcl-2 alters regulators of cell adhesion and migration leading to a more aggressive invasive phenotype.
In this study, we investigated how elevated levels of Bcl-2 altered the invasive behavior of HNSCC cells. We find that overexpression of Bcl-2 in squamous carcinoma cells dramatically enhanced tumor metastasis to the lung and correlated with elevated cell motility and invasion. Furthermore, Bcl-2 altered the ability of squamous carcinoma cells to efficiently form cell-cell contacts, which led to increased cell scattering and inability to form strong multi-cell adhesions. These morphologic changes reflected an EMT, which involved multiple changes in gene expression including alterations in cadherin expression and induction of mesenchymal markers, leading to an increase in metastatic potential. Thus, upregulation of Bcl-2 in advanced stage cancer may facilitate the evolution of cells into more aggressive variants as a result of EMT processes that replicate signaling cascades found in developmental programs.
Materials and Methods

Antibodies and Inhibitors
The following monoclonal antibodies were used: E-cadherin (HECD-1 from Dr M. Takeichi, Kyoto University, Kyoto, Japan), N-cadherin (Zymed), ZO1 (Epitomics), and vimentin and β-tubulin (BD Pharmingen). E-cadherin (H-108) and Bcl-2 were purchased from Santa Cruz Biotechnology. Phosphorylated extracellular signal-regulated kinase (ERK)-1/2 and total-ERK1/2 were purchased from Cell Signaling Technology. Antimouse and antirabbit secondary antibodies, conjugated to horseradish peroxidase for immunoblotting or conjugated to FITC, were obtained from Jackson ImmunoResearch Laboratories. Rhodamineconjugated phalloidin was obtained from Molecular Probes. The pharmacologic inhibitors used were epidermal growth factor receptor (EGFR) inhibitor (tyrphostin AG1478, Calbiochem), mitogen-activated protein kinase (MAPK)-1/2 and ERK1/2 inhibitor (U0126, Promega), fibroblast growth factor receptor (FGFR) inhibitor (PD173074, Pfizer), and matrix metalloproteinase (MMP) inhibitor (GM6001, Calbiochem).
Cell Culture and Transfection
The squamous carcinoma HSC-3 cell line was derived from a cervical lymph node metastasis of a tongue primary lesion, has been shown to retain both its in vivo tumorigenicity and metastatic potential in the nude mouse model, and has been extensively characterized for its in vitro and in vivo phenotypes (26) (27) (28) (29) (30) (31) (32) . The HSC-3 squamous cell carcinoma cell line was routinely obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank. Cells were normally maintained at low passage in DMEM supplemented with 10% fetal bovine serum. The JCRB Cell Bank authenticated cell identification by using short tandem repeat analysis of loci with the PCRbased PowerPlex1.2 system (33). When received from JCRB, cells were expanded and frozen stocks were prepared. For experiments, cells were used at low passage for not more than 6 mo before replenishing with fresh samples from the frozen stocks.
The generation of the Bcl-2-expressing cell line was described previously (26) . Briefly, for constitutive expression of Bcl-2, HSC-3 cells were transfected with Bcl-2 in a pcDNA3 vector and the stably transfected cells were selected with G418 to yield the Bcl-2 cell line. The cell line, which was not subsequently cloned, exhibited elevated levels of ectopically expressed Bcl-2, as confirmed by immunoblot analysis (24) . Similarly, the mock-transfected cell line was generated from HSC-3 cells using an empty vector. Cloned cells lines were not used in the current study.
For RNA interference analysis, siRNA targeting human N-cadherin (CDH2 Smartpool, Dharmacon) was delivered into Bcl-2 cells using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. In addition, nontargeting siRNA pool (Dharmacon) was used at the same concentration as a control for the RNA interference assays. After 48 h of transfection, cells were subjected to migration and invasion assays as described below or cell lysates were collected and analyzed by Western blot.
Tumorigenicity and Experimental Metastasis Assays
NIH BALB/c female mice were housed in University of California San Francisco animal facilities as approved by the Institutional Animal Care and Use Committee. Groups of mice were used for the tumorigenicity assay in which the indicated number of tumor cells was injected s.c. in the right flank. The mice were monitored daily and tumors were measured using a caliper for 21 d, at which time the experiments were terminated due to the tendency of the HSC-3 cells to become necrotic and form skin ulcers (34) .
For experimental metastasis assays, groups of mice were injected i.v. in the lateral tail vein with 100 μL of serumfree DMEM containing either control cells or Bcl-2-expressing cells. After 6 wk, mice were sacrificed; lungs were removed, fixed in Bouin's solution, and examined with a dissecting microscope and scored for visible surface tumors. In addition, samples were processed for histologic analysis by embedding in paraffin and sectioning.
Migration and Invasion Assays
In the transwell migration assay, the underside of the transwell (8 μm pore size; Corning Costar Corp.) was precoated with collagen type I (Col-I; 1 μg/mL), fibronectin (10 μg/mL), and laminin-111 (Ln-1; 10 μg/mL). Next, 2 × 10 5 cells were loaded onto the upper chamber of the transwell and the lower chamber was filled with serum-free medium. Cells were incubated for 3 or 6 h at 37°C, fixed with 4% paraformaldehyde, and stained with crystal violet. Nonmigrating cells retained on the upper side were removed by wiping with a cotton swab. Cells that had migrated through the filter were counted and averaged from 10 randomly chosen microscopic fields using a 20× objective.
Time-lapse video microscopy was done as described (35) with slight modifications. Briefly, cells were seeded onto six-well plates (Falcon, Becton Dickinson Labware) coated with different substrates, Col-I (1 μg/mL) or fibronectin (10 μg/mL), and maintained at 37°C and 5% CO 2 . Plates were then examined under a Zeiss Axiovert inverted microscope and relative cell velocity was determined as described previously (35) . In vitro invasion assays were done using transwell inserts (Corning), which consisted of cell culture inserts containing 8 μm pore size filters. Briefly, the transwell inserts were coated with Matrigel (1 mg/mL) or Col-I (1.2 mg/mL) and allowed to gel at 37°C for 1 h. Next, cells (2 × 10 5 ) in 200 μL of serum-free DMEM were added on top of the transwell. Serum-free medium was then added to the lower chamber and incubated for 24 h at 37°C. Cells were fixed and stained with crystal violet. Matrigel gel and associated cells were removed with a cotton swab. Cells that had penetrated the Matrigel gel or Col-I and had reached the underside of the filter membrane were then counted in 10 randomly chosen microscopic fields using a 20× objective. Data were expressed as the mean ± SD of the number of migrated cells or, alternatively, as the relative percentage of migratory cells in the experimental compared with that of control cells.
Cell Scatter Assay
Subconfluent cell monolayers were treated briefly with trypsin-EDTA to prepare single-cell suspensions (2 × 10 4 cells/mL) in DMEM. To generate cell aggregates, the cell suspension was plated in polyHEMA-coated plates and incubated for 12 h in 5% CO 2 at 37°C. Cell aggregates were transferred to Col-I-or fibronectin-coated six-well plates. Plates were maintained at 37°C and 5% CO 2 and examined by time-lapse microscopy as above.
Immunoblotting and Gelatinolytic Zymography
Cells were extracted using lysis buffer [50 mmol/L Tris (pH 7.5), 500 mmol/L NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 10 mmol/L MgCl 2 , and complete protease inhibitor mixture (Roche Molecular Biochemicals)]; protein concentrations were measured with the bicinchoninic acid protein assay kit (Pierce) and processed for SDS-PAGE. After transferring onto nitrocellulose membranes (Millipore Corp.), proteins were probed with primary antibodies and secondary horseradish peroxidase-coupled antibodies. Blots were developed by chemiluminescence using the enhanced chemiluminescence system (Amersham Biosciences). Gelatinolytic zymography of MMP-9 activity was done in 7.5% (w/v) SDS-polyacrylamide gels containing 2.56 mg/mL gelatin under nonreducing conditions.
Real-time PCR
Cells cultured for 48 h in growth medium were serum starved 24 h before RNA extraction (Qiagen RNeasy Mini Kit). The following forward and reverse primers were used: N-cadherin, 5′-caacttgccagactccagg-3′, 5′-atgaaaccg ggctatctgctc-3′; E-cadherin, 5′-gacaaaaccatacgcaatcctc-3′, 5′-tccgttctctcaaagatgttgc-3′; glyceraldehyde-3-phosphate dehydrogenase, 5′-tggcagagatgcgtggaga-3′, 5′-ggcaagtcttccgagtagtttt-3′; and MMP-9, 5′-ctctgctcctcctgttcgac-3′, 5′-ttgattttggagggatctcg-3′. The PCR conditions used were as follows: 5-min denaturation at 95°C followed by 40 cycles at 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s. Amplification of the target gene was monitored as a function of increased SYBR Green I fluorescence. An analysis threshold was set, and the cycle threshold (Ct) was computed for each sample. The comparative difference in gene expression was then determined.
N-cadherin Promoter Assay
HEK293 cells were cultured in DMEM containing 10% fetal bovine serum in 5% CO 2 at 37°C. For transient transfection, briefly, 4 × 10 5 cells were plated in 35-mm plates in DMEM plus 10% fetal bovine serum. After 12-h incubation, the cells were transfected with an N-cadherin promoter fragment using the Lipofectamine Plus (Invitrogen) transfection reagent. The 6.0-kb fragment containing the N-cadherin promoter was cloned into pGL3 vector. 3 Bcl-2 was cotransfected with a plasmid expressing the N-cadherin promoter. As an internal control for transfection efficiency, 10 ng of pRL-TK were used. At 48 h after transfection, cells were harvested and assayed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega).
Statistical Analysis
Student's t test was used for the statistical analysis of interval data, with P < 0.05 considered as significant.
Results
Bcl-2 Overexpression Promotes Tumorigenesis and Pulmonary Metastasis
To investigate the role of Bcl-2 in the invasiveness and metastatic potential, we took the approach of overexpressing Bcl-2 in the HNSCC cell line HSC-3, which normally expresses background levels of Bcl-2 protein. The Bcl-2 cell line was previously characterized (26, 27) and represents a stable population of cells derived by transfection with an experimental plasmid (Fig. 1A) . Initially, we examined whether Bcl-2 overexpression could potentiate tumorigenesis. When we injected the animals with 5 × 10 5 control cells, 60% (3 of 5) of the mice developed subcutaneous tumors, whereas 100% (5 of 5) mice formed tumors with Bcl-2-expressing cells. In another group of animals injected with a higher number of cells (1 × 10 6 ), 100% the animals formed tumors for both mock and Bcl-2 cells. Measurement of the tumor size revealed that by 9 to 14 days, the average volume of the tumors from mice bearing Bcl-2-expressing cells indicated a significantly greater growth rate compared with mock-transfected cells (Fig. 1B) .
We next sought to investigate the effect of Bcl-2 overexpression on experimental metastasis by analyzing the formation of pulmonary tumor nodules following tail vein injection. Although there was no visible tumor outgrowth in the lungs of mice (0 of 5) injected with 1 × 10 6 control cells, we observed pulmonary metastatic lesions in all animals (5 of 5) injected with Bcl-2 cells (Fig. 1C and D) . However, in separate experiments in which we injected a higher number of input cells (3 × 10 6 ), 36% (4 of 11) of the mice injected with control cells showed tumor growth in the lungs. All mice (10 of 10) injected with Bcl-2-expressing cells developed surface nodules (P < 0.05) that represented up to an 18-fold increase compared with those injected with control cells (Fig. 1D, right) . Analysis of H&E-stained lung sections showed that injection of Bcl-2-overexpressing cells formed abundant tumors within the lung parenchyma with much larger cross-sectional tumor surface areas compared with the control group (Fig. 1E) .
Overexpression of Bcl-2 Induces Loss of Epitheloid Phenotype
HSC-3 cells grown in culture at high densities show a classic epitheloid morphology, including growth in islands of closely apposed cells with cobblestone appearance. FIGURE 2. Bcl-2 induces an EMT phenotype and increases cell scattering. A, representative phase-contrast images of control, mock, and Bcl-2-expressing HSC-3 cells. B, cells as indicated were detached and subjected to forced cell aggregation for 12 h. Cell aggregates were then collected and seeded onto Col-I-coated (1 μg/mL) culture plates and monitored by time-lapse video microscopy. Bcl-2 cells show an immediate out-migration from aggregates whereas the control cells were severely delayed. C, dispersion of cell aggregates shown in B were then assessed for scattering as described in Materials and Methods. The data were expressed as the relative scatter index. Points, mean; bars, SE (*, P < 0.01). D, representative images are shown for cell scattering after 18 h on fibronectin (Fn)-coated substrates.
In contrast, Bcl-2 cells showed a strong scattered phenotype, losing their tight arrangement of cell-cell junctions and becoming spindle-shaped ( Fig. 2A) . These morphologic changes are reminiscent of cells of the mesenchymal lineage. To further evaluate the above observations, we carried out cell scatter assays on Col-I-coated plates. Remarkably, aggregates from Bcl-2-overexpressing cells rapidly attached to the substrate and displayed brisk cell dispersion over time where many of the clustered cells shifted to mainly solitary migrating cells (Fig. 2B) . In contrast, control or mock cells showed a sluggish tendency to scatter and remained primarily as aggregated cell clumps even after 18 hours of incubation. Measurement of the cell scatter area by Bcl-2 cells showed nearly an 8-fold greater dispersion than that of control cells (Fig. 2C) . The acquired cell scatter effect of Bcl-2-transfected cells was also visualized on two other substrates, fibronectin (Fig. 2D ) and laminin 332 (data not shown). 
Bcl-2 Overexpression Induces N-cadherin Expression
Because Bcl-2-expressing cells exhibited morphologic changes with a higher tendency of cell scattering effect, we wondered whether the expression patterns of critical epithelial specific proteins were altered. In control and mock-transfected cells, Western blot analysis detected high levels of known epithelial marker proteins, desmoglein-3, zonula occludin-1, cytokeratin, and E-cadherin (Fig. 3A) . However, in Bcl-2 cells, there was a significant attenuation of this set of proteins. The expression of E-cadherin was further evaluated using flow cytometry analysis, which confirmed that the surface E-cadherin in Bcl-2 cells was suppressed by more than 50% compared with control cells (Fig. 3B) . Furthermore, quantitative PCR showed that Bcl-2 expression significantly suppressed E-cadherin mRNA levels (Fig. 3C) .
The above alterations in cell morphologic phenotype and the downregulation of important epithelial protein markers in Bcl-2-overexpressing cells resemble the process of EMT. EMT frequently occurs during tumor progression as primary epithelial tumors transform to more aggressive metastatic tumors. We therefore analyzed the expression of a set of mesenchymal protein markers that have been shown in other studies to correlate with EMT. Immunoblotting analysis showed that N-cadherin, vimentin, and fibronectin were highly upregulated in Bcl-2 cells compared with control or mock cells (Fig. 3D) .
The induction of N-cadherin with the concurrent attenuation of E-cadherin is an important cellular event observed during EMT (36) . To further define how this important EMT marker in Bcl-2-expressing cells is induced, we first confirmed the induction of N-cadherin mRNA by quantitative PCR. As shown in Fig. 3E , the level of N-cadherin expression in Bcl-2 cells was enhanced by more than 15-fold compared with control and mock cells (Fig. 3E ). Next, we tested if Bcl-2 expression drives N-cadherin expression at the promoter level. In the first approach, HEK293 cells were transiently cotransfected with the N-cadherin promoter and Bcl-2 constructs. The results showed that transfection of Bcl-2 strongly elevated N-cadherin promoter activity as compared with N-cadherin promoter alone (Fig. 3F , compare column 2 to column 3). EF1, a known positive transcriptional regulator of N-cadherin, was highly efficient in activating promoter activity (Fig. 3C, column 4) . Using a more relevant approach, we transiently transfected the N-cadherin promoter directly into control HSC-3 and Bcl-2-expressing cells. The results show that in control HSC-3 cells, the N-cadherin promoter activity was <2-fold higher compared with cells transfected with vector alone (Fig. 3G) . However, in Bcl-2-overexpressing cells, the induction of N-cadherin promoter activity was enhanced by almost 18-fold compared with vector controls.
The Snail-related set of transcription factors that repress or activate E-cadherin and N-cadherin expression are considered critical regulators of EMT (37) . Because overexpression of Bcl-2 in HSC-3 cells induced EMT-like characteristics, we performed a preliminary PCR analysis to examine the presence of known EMT regulatory molecules in Bcl-2-expressing cells, including Snail1, SIP1, slug, zeb1, and twist. However, no differences were detected in the expression of these transcription factors between Bcl-2-expressing and control cells (data not shown).
Bcl-2 Overexpression Enhances Cell Motility and Invasion
The acquisition of an EMT phenotype and the enhanced cell scattering prompted us to evaluate the migration and invasion ability of Bcl-2-overexpressing cells. As shown in Fig. 4A , Bcl-2 cells migrated faster than the parental or mock controls on Col-I substrates in transwell assays. Bcl-2 cells also showed enhanced migration on fibronectin and Ln-1 substrates, although at a lower level compared with Col-I. Next, cell motility of Bcl-2 cells was studied by time-lapse video microscopy. Compared with control cells, Bcl-2 cells showed increased average velocity on Col-I (Fig. 4B, left) . Cell trace analysis depicting the movement of individual cells also revealed a significant increase in cell motility among Bcl-2 versus control cells (Fig. 4B, right) . In addition, Bcl-2 cells tended to show a more directed persistence than control cells. We observed a similar pattern of cell motility by Bcl-2 cells on fibronectin and Ln-1 (data not shown). We next tested the invasive capacity of the cell line through the ECM barriers. We found that Bcl-2 cells showed a dramatic increase in invasion compared with control cells toward both Matrigel and Col-I matrices ( Fig. 4C and D) . The data suggest that Bcl-2 expression and the acquisition of an EMT-like phenotype paralleled the induction of enhanced motility and invasive ability of squamous carcinoma cells.
Bcl-2-Induced N-cadherin Expression Regulates Squamous Carcinoma Cell Migration and Invasion
To examine if the increased migration and invasive potential of Bcl-2 cells was related to N-cadherin induction, we analyzed the effect of N-cadherin knockdown by targeting with specific siRNA. The siRNA was efficient in reducing N-cadherin compared with the control scrambled oligonucleotide (Fig. 5A) . Having confirmed the N-cadherin knockdown, we next measured the migration and invasion ability of these cells. We found that the number of migrating Bcl-2 cells following N-cadherin suppression was significantly decreased compared with that of the untreated or control cells (Fig. 5B) . The observed inhibition of cell migration was similar whether the transwells were coated with Col-I, fibronectin, or Ln-1. Cell invasion assays with Matrigel barriers also showed that suppression of N-cadherin expression significantly reduced the number of invading cells (Fig. 5C ). At the same time, we found that knockdown of N-cadherin dramatically attenuated MMP-9 production compared with controls (Fig. 5D ).
Bcl-2 Promotes Persistent ERK Signaling and Elevates MMP-9 Production
To further define the mechanism of Bcl-2-induced cell motility, we examined critical signaling components known to regulate cell migration and invasion. We found that ERK phosphorylation was increased in Bcl-2 cells compared with controls (Fig. 6A) . The increase in steady-state levels of ERK phosphorylation was observed whether Bcl-2 cells were incubated in the presence or absence of 10% serum before analysis (data not shown). The presence of constitutive ERK activity in metastatic tumor cells has been shown to be associated with enhanced MMP-9 expression and induction of invasive capacity (38) . We observed that Bcl-2-overexpressing cells elevated MMP-9 production about 3-fold greater compared with controls (Fig. 6A) . Quantitative PCR also showed that Bcl-2 expression significantly induced MMP-9 expression (data not shown). Next, we directly tested whether ERK activity was contributing to the increased migration and invasiveness of Bcl-2-overexpressing cells. As expected, the MAP/ERK kinase-1/2 and ERK inhibitor U0126 could efficiently inhibit ERK phosphorylation in a dosedependent manner (Fig. 6B) . Bcl-2-expressing cells showed coordinate loss of MMP-9 expression following inactivation of MAPK/ERK signaling with U0126.
Consistent with these results, we found that treatment of Bcl-2-overexpressing cells with 1 or 5 μmol/L U0126 reduced their migratory activity (Fig. 6C) . Next, we determined the invasive ability of Bcl-2-overexpressing cells through Matrigel barrier after treatment with U0126 or GM6001, a potent nonselective MMP inhibitor that also targets MMP-9. We found that suppression of MAPK/ ERK signaling with 1 and 5 μmol/L U0126 led to reduction of invading cells by 48% and 73%, respectively, as compared with DMSO control (Fig. 6D) . Abrogating MMP activity with 1 μmol/L GM6001 also reduced cell invasion by about 54% when compared with Bcl-2 cells treated with DMSO alone. These results support the possibility that the increased cell invasion induced by Bcl-2 overexpression involves increased MMP-9 expression through an ERK-dependent signaling pathway. N-cadherin has been shown to promote invasion by stabilization of the FGFR, which can in turn activate ERK (38) (39) (40) . To test this possibility in Bcl-2-overexpressing cells, we first asked whether blocking the expression of N-cadherin by siRNA alters the ERK activation. Following FIGURE 4. Bcl-2 overexpression promotes migration and invasion. A, control, mock, and Bcl-2-expressing cells were subjected to 3-h and 6-h migration assays using transwells coated with fibronectin, Ln-1, and Col-I substrates. The number of cells that migrated through the transwell membranes was estimated by counting at least 10 random microscopic fields. Columns, mean; bars, SD (*, P < 0.001). B, cell velocity on Col-I-coated substrates was measured by time-lapse video microscopy (left; *, P < 0.05). Representative cell tracks on Col-I substrate are shown (right). C and D, cells invasion assays were done for 24 h on transwells coated with Matrigel (C) or Col-I (D) as described in Materials and Methods. The number of cells that migrated through the transwell membranes was determined by counting at least 10 random microscopic fields. Columns, mean; bars, SD (*, P < 0.05).
the loss of N-cadherin expression (Fig. 5A) , there was a parallel suppression of ERK phosphorylation (Fig. 7A ). Next, we tested if the FGFR/ERK signaling pathway played a role in mediating the enhanced invasive activity of Bcl-2 cells. Treatment of Bcl-2 cells with 0.5 or 1 μmol/L of the FGFR inhibitor PD173074 was sufficient to suppress elevated ERK phosphorylation (Fig. 7B) . In contrast, use of 0.5 or 1 μmol/L of the EGFR inhibitor AG1478 produced only a minor suppression of ERK phosphorylation in Bcl-2 cells, whereas as expected, AG1478 strongly inhibited EGFR activity (Fig. 7C) . This suggests that the enhanced ERK activity observed in Bcl-2-overexpressing cells is primarily propagated through the FGFR pathway rather than EGFR. Furthermore, PD173074 at 1 μmol/L caused a marked reduction in motility of Bcl-2 cells, whereas the FGFR inhibitor had no effect on the locomotion of control cells (Fig. 7D) . Similarly, PD173074 effectively reduced Bcl-2 cell invasion whereas the FGFR inhibitor produced no detectable effect on control cells (Fig. 7E) . The data suggest that in cells overexpressing Bcl-2, N-cadherin engages the FGFR axis, leading to enhanced ERK signaling, stimulating the migration and promoting an invasive phenotype.
Discussion
The findings presented here identify the potential mechanisms by which overexpression of Bcl-2 can lead to the acquisition of enhanced metastatic potential in HNSCC cells. We show that ectopic Bcl-2 expression in HSC-3 cells (a) enhances tumor growth and pulmonary metastasis, (b) promotes an EMT-like phenotype with an increase in N-cadherin expression, (c) supports enhanced cell locomotion and invasion, and (d) induces MMP-9 production through a FGFR/ERK signaling-dependent pathway. These findings indicate that Bcl-2 modulates multiple cell adhesion and migratory functions in addition to its ability to inhibit apoptosis.
It is expected that Bcl-2, a member of the antiapoptotic family, would promote cell survival, thereby favoring metastatic progression. The current results with HNSCC cells support previous findings that Bcl-2 can promote metastasis in different tumor cell types (2, 19, 41, 42) . Our study shows that overexpression of Bcl-2 leads to HNSCC cells with a more malignant phenotype including an enhanced tumorigenic and metastatic potential. Most HNSCC cells normally exhibit an epitheloid morphology forming tight monolayers with well-formed junctions. Bcl-2-transfected cells formed only limited and transient cell-cell adhesions and instead generated a partial EMT phenotype, with an increased propensity for cell scattering. Concurrent with these changes was the induction of a number of additional alterations including the induction of mesenchymal markers vimentin and fibronectin and loss of tight junction, zonula adherens, and desmosomal-associated proteins. E-cadherin expression was also suppressed and is well known to undergo transcriptional repression during EMT. This observation is similar to a previous study showing a reduction in E-cadherin following Bcl-2 overexpression in a normal breast epithelial cell line (24) . The Bcl-2-mediated morphologic conversion to an EMT phenotype proceeded with a parallel induction of N-cadherin, an intercellular adhesion receptor that has been associated with a more aggressive and invasive behavior in a number of tumor types including breast, prostate, and HNSCC (38, 43, 44) .
Proteolytic degradation of the basement membrane and of the underlying stromal ECM by MMPs represents an important component of the invasion-metastasis cascade (45) (46) (47) . In particular, MMP-9, which is expressed by many types of human carcinomas, has been closely associated with invasion and confers metastatic ability to normal cells (36, 46, 48) . We found that N-cadherin-expressing Bcl-2 cells strongly increased MMP-9 transcription and enhanced enzyme production. Moreover, silencing of N-cadherin reduced the Bcl-2-mediated upregulation of MMP-9, thus establishing a link between cadherin expression and elevated MMP-9. Our finding is consistent with previous reports showing N-cadherin-mediated induction of MMP-9 gene expression (38, 49) .
Our data suggest that the upregulation of N-cadherin expression correlated with a number of diverse changes associated with Bcl-2 induction of EMT. Previous work has shown that switching of E-cadherin to N-cadherin leads to a more malignant phenotype (50) . Importantly, our data also show that the increased N-cadherin seen after Bcl-2 overexpression can influence MMP-9 expression and tumor invasion through the ERK signaling pathway. We found that Bcl-2 cells exhibit high and persistent levels of phosphorylated ERK. This is potentially significant because such sustained levels of ERK phosphorylation may dysregulate diverse biological functions including proliferation, survival, differentiation, and invasion (51). Thus, there seems to be a relationship between the upregulation of N-cadherin in Bcl-2-expressing cells and the activation of ERK signaling-dependent MMP-9 production leading to facilitated cell invasion.
A number of studies suggest the binding and stabilization of FGFR by N-cadherin as a mechanism to promote enhanced ERK signaling and cell invasiveness (38) (39) (40) 50) . In support of this mechanism, we found that inhibiting FGFR in Bcl-2 cells caused a parallel sharp reduction in phosphorylated ERK levels and a corresponding decrease in cell migration and invasiveness. The precise mechanism of how the FGFR signals in Bcl-2-expressing cells is unclear and will require additional work. Nevertheless, our findings are consistent with a process involving elevated N-cadherin induced by overexpression of Bcl-2 that, in turn, increases ERK phosphorylation via FGFR activation.
It is now appreciated that EMT is not always an all-ornone response. There are many studies showing epithelial cells taking on varying degrees of the mesenchymal-like phenotype, and this formation of partial EMT may be more common than the classic full-blown EMT (52) (53) (54) . In addition, full EMTmay require a gradual progressive staged process, but limited EMT may exist transiently (37, 55) . For example, collective migration of epithelial cells involves cells that take on some mesenchymal characteristics but maintain FIGURE 6. Bcl-2 overexpression induces sustained MAPK activation. A, whole-cell lysates prepared from control, mock, and Bcl-2-expressing cells were immunoblotted with antibodies to phospho-ERK1/2 or total ERK1/2. Immunoblotting for Bcl-2 and tubulin was also done. Conditioned medium collected from the cell lines were analyzed by gelatin zymography. B, effect of MAP/ERK kinase/ERK inhibitor on MMP-9 expression. Bcl-2-expressing cells were treated with DMSO alone or with 1 and 5 μmol/L U0126 for 18 h. Cells lysate were prepared and analyzed by immunoblotting with anti-phospho-ERK1/2 or anti-total ERK1/2. Conditioned medium collected from the inhibitor-treated cells was assayed for MMP-9 levels by gelatin zymography. C, Bcl-2 cells treated with either DMSO or 1 and 5 μmol/L U0126 were tested for migration through Col-I-coated transwells. Columns, mean; bars, SD (**, P < 0.05; ***, P < 0.001). D, Bcl-2 cells treated with DMSO vehicle, U0126 (1 and 5 μmol/L), or GM6001 (1 μmol/L) were assayed for invasion through Matrigel-coated filter inserts. Columns, mean; bars, SD (*, P < 0.05; **, P < 0.001).
certain epithelial properties. Also, it is interesting that in Bcl-2-overexpressing cells, E-cadherin is still expressed but at lower levels, yet the receptor fails to confer an epithelial phenotype as they display enhanced invasion and metastasis. It is also possible that the induction of MMPs such as MMP-9 in Bcl-2-overexpressing cells may directly promote partial EMT by promoting the degradation and processing of the ECM (56) .
Collectively, the present work has provided new insights on how elevated expression of antiapoptotic Bcl-2 not only enhances carcinoma cell survival but also increases malignant behavior leading to increased invasion and dissemination. In this regard, overexpression of Bcl-2 would be expected to increase metastatic colonization as the embolic tumor cells would be resistant to anoikis. Simultaneously, Bcl-2 also increases tumorigenicity and, through induction of an EMT-like phenotype, triggers an invasion-metastatic profile. Thus, there may be multifactoral elements derived from Bcl-2 expression that drive overall tumor progression.
It remains unclear exactly the means by which Bcl-2 can induce such a diverse set of crucial signaling events culminating in enhanced metastatic potential. At this time, it is difficult to link the enhanced metastatic activity to a specific trait induced by overexpression of Bcl-2. Additional work is needed to discover how elevated Bcl-2 triggers this striking transformation in cell behavior that seems to involve EMT, either directly or through intermediate signaling pathways. Snail1, SIP1, and twist are important transcription factors known to be involved in the switching of E-cadherin to N-cadherin during EMT. Despite the expression of various markers indicative of EMT, we did not detect induction of any of these transcription factors following overexpression of Bcl-2.
It is possible that alternative mechanisms are operational in this model system that convert epithelial cells into more (Fig. 5A) were analyzed for phosphorylated-ERK, which was then processed and reprobed for total ERK. B, Bcl-2 cells were treated with vehicle alone or with the indicated concentration of the FGFR inhibitor (PD173074) for 18 h. Cell lysates were prepared and analyzed by immunoblotting with antibodies to phospho-ERK1/2 or total ERK1/2. C, Bcl-2 cells were treated for 18 h with DMSO alone or with the EGFR inhibitor (AG1478) as indicated. Cell lysates (CL) were then prepared and analyzed by immunoblotting with antibodies to phospho-ERK1/2 or total ERK1/2. Cell lysates were also subjected to immunoprecipitation (IP) with anti-EGFR and detected by immunoblotting with antibody to phosphorylated EGFR (pY1173). D and E, control and Bcl-2 cells treated with vehicle or 1 μmol/L PD173074 were tested for their ability to migrate (D) or invade (E) through Col-I barriers in transwell chambers. Columns, mean; bars, SD (*, P < 0.05; **, P < 0.001).
mesenchymal cells. For example, the T-box transcription factor Tbx3, like snail and slug, was recently shown to downregulate the E-cadherin promoter (57) . Similarly, β-catenin-LEF-1 complexes can directly promote EMT and acquisition of the mesenchymal phenotype without upstream signaling pathways involving snail family transcription factors (58) . However, our study indicates that Bcl-2 overexpression regulates N-cadherin expression at the transcriptional level, and it will be important to identify the specific mechanism by which Bcl-2 upregulates N-cadherin expression. Our findings provide a basis for further characterization of the molecular mechanisms of N-cadherin-mediated invasion that cooperate with the regulation by Bcl-2 family members of antiapoptotic function in the development of highly metastatic cell variants in HNSCC.
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